Clinical Trials Logo

Recurrent/Refractory Glioblastoma clinical trials

View clinical trials related to Recurrent/Refractory Glioblastoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT02626364 Recruiting - Clinical trials for Recurrent/Refractory Glioblastoma

Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification

Start date: April 2016
Phase: Phase 2
Study type: Interventional

This is a proof of concept, single-arm study to investigate crenolanib monotherapy in patients with recurrent/refractory glioblastoma with PDGFRA gene amplification by assessing the progression-free survival (PFS) at 6 months. Crenolanib will be given orally starting at 100 mg TID continuously until disease progression, unacceptable toxicity, or consent withdrawal.